Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. (INDV): 9 pipeline candidates · 2 upcoming catalysts · ~108 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
107.5 months
D/E -9.31
Lead: Approved
9 candidates
2 upcoming, next in ~605d
8 buys · 0 sells (180d)
A transparent, data-derived signal for Indivior Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.5B
Cash
$175.0M
Quarterly Burn
$9.0M
Runway
107.5 mo
Revenue
$317.0M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| extended-release buprenorphine | Phase 4 |
| indv-2000 | Phase 2 |
| indv-6001 | Phase 2 |
| opvee | Approved |
| perseris kit | Approved |
| sublocade | Phase 4 |
| suboxone | Phase 4 |
| tm buprenorphine | Phase 4 |
| transmucosal buprenorphine | Phase 4 |
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
289
Total value held
$3.84B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 18,542,220 | $565.2M |
| vanguard capital management llc | 11,173,152 | $340.6M |
| vanguard portfolio management llc | 7,891,819 | $240.5M |
| oaktree capital management lp | 6,984,102 | $212.9M |
| state street corp | 4,903,993 | $149.5M |
| two seas capital lp | 4,746,510 | $144.7M |
| millennium management llc | 4,595,535 | $140.1M |
| fuller & thaler asset management, inc. | 4,529,583 | $138.1M |
| citadel advisors llc | 3,705,044 | $112.9M |
| morgan stanley | 3,505,817 | $106.9M |
Showing top 10 of 289 institutional holders of Indivior Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Indivior Pharmaceuticals, Inc.'s pipeline?
Indivior Pharmaceuticals, Inc. (INDV) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Indivior Pharmaceuticals, Inc.'s lead drug candidate?
Indivior Pharmaceuticals, Inc.'s most advanced tracked candidate is extended-release buprenorphine (Phase 4) for Moderate to Severe Opioid-use Disorder.
What is Indivior Pharmaceuticals, Inc.'s next catalyst?
Indivior Pharmaceuticals, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: PERSERIS KIT" — expected February 13, 2028.
What is Indivior Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Indivior Pharmaceuticals, Inc. has approximately 107.5 months of cash runway.
What is Indivior Pharmaceuticals, Inc.'s market capitalization?
Indivior Pharmaceuticals, Inc.'s market capitalization is approximately $4.5B.
Get the full picture on Indivior Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.